Aethlon Earnings Call Balances Trial Progress With Cash Risk

Aethlon ((AEMD)) has held its Q3 earnings call. Read on for the main highlights of the call.

Aethlon’s latest earnings call painted a cautiously optimistic picture, pairing tangible clinical and R&D advances with a tightening financial backdrop. Management highlighted encouraging safety data and expanding science around its Hemopurifier platform, yet acknowledged a modest cash balance, higher quarterly losses, and lingering uncertainties around trial timelines and new delivery systems.

Australian Oncology Trial Shows Safety and Early Biological Signals

Cohort 1 of the Australian oncology trial has been completed, with three patients receiving a single Hemopurifier treatment and experiencing no device-related serious adverse events or dose-limiting toxicities. Early signs of biological activity emerged as directional improvements were seen in extracellular vesicle counts and immune cell numbers, offering a preliminary but encouraging efficacy signal.

Cohort 2 Progress and Imminent DSMB Decision

In Cohort 2, two patients have completed two Hemopurifier treatments and a third patient is enrolled and expected to be treated by the end of February. An independent DSMB review is targeted for late March and is expected to decide quickly whether the trial can advance to Cohort 3 or must enroll three additional patients in Cohort 2, keeping short-term outcomes and dosing strategy uncertain.

Expanding EV Research Underpins Multi-Indication Potential

Management emphasized growing extracellular vesicle research that supports Hemopurifier as a potential platform therapy across multiple indications. Recent work includes a published trial design in BMJ Open, preclinical Long COVID data showing the resin binds EVs and reduces microRNAs linked to immune dysregulation, and prior findings on platelet-derived EV clearance, with further disease-plasma studies and cargo exploration planned.

SLAMB Workstream Targets Simpler, Less Invasive Delivery

Aethlon is testing compatibility of its Hemopurifier with the SLAMB system, which uses a single small-lumen catheter and a simplified pump instead of dialysis machines and large double-lumen catheters. If successful, this could shift treatment into oncology units or infusion centers using PICC-like lines, potentially reducing invasiveness, logistics burden, and setting costs for future use.

Cost Discipline Drives Significant Year-to-Date Savings

For the nine months ended December 31, 2025, consolidated operating expenses dropped to $5.36 million from $7.34 million a year earlier, a 27% reduction. The decline was driven by lower payroll, general and administrative expenses, and professional fees, signaling tighter cost control as the company seeks to preserve cash while advancing its clinical and research programs.

Enrollment Efforts Gain Traction Through External Partners

To support faster trial recruitment, Aethlon has engaged Trialfacts for online outreach and Dedicated for phone-based prescreening of potential participants. These efforts have created a growing referral pool for investigative sites, giving the company a ready queue of candidates that could accelerate movement into Cohort 3 once DSMB approval is obtained.

Quarterly Operating Costs and Loss Move Higher

Despite year-to-date savings, quarterly expenses moved in the opposite direction, with operating costs for the three months ended December 31 rising to about $2.06 million, up 13.6% year over year. The operating loss widened to $2.06 million from $1.81 million, underscoring the financial impact of ongoing clinical and R&D activity in the near term.

Other Income Slips on Lower Interest Earnings

Other income, primarily interest on cash balances, declined to $44,000 for the quarter from $60,000 in the same period last year. The drop in interest income, though modest in absolute terms, further contributed to the wider bottom-line loss and reflects the company’s smaller effective return on its cash resources.

Limited Cash Balance Highlights Funding Risk

Aethlon reported cash of roughly $7.0 million as of December 31, 2025, providing only a modest financial cushion relative to its quarterly expense base. While management did not specify runway, the balance suggests constrained flexibility and raises the possibility that additional financing could be required depending on pace of clinical progress and spending levels.

SLAMB Pathway Still Early with Regulatory Hurdles Ahead

The SLAMB system remains at a preliminary stage, with current work confined to lab and ex vivo compatibility testing and no FDA approval in place. Management noted that further studies on flow dynamics and EV capture, along with regulatory submissions, will be necessary, meaning SLAMB is unlikely to influence the present trial or near-term commercialization timelines.

Trial Scale and Dosing Outcomes Yet to Be Proven

The Australian study remains a small 9–18 patient safety and feasibility trial, and key questions on efficacy and optimal dosing—whether one, two, or three treatments per week—are still unanswered. The DSMB may require additional Cohort 2 patients before moving to the more intensive Cohort 3 schedule, keeping both progression timing and future development strategy in flux.

India Expansion Shelved to Preserve Focus and Capital

Aethlon elected not to re-engage clinical sites in India for additional safety trials, citing a desire to avoid distractions and incremental expense. While this limits geographic diversification of enrollment, it aligns with management’s emphasis on concentrating resources on the Australian trial and core development priorities under a tightened budget.

Guidance Underscores Tight Capital Management and Near-Term Milestones

Management reiterated its focus on disciplined capital deployment, pointing to the $7.0 million cash position, quarterly operating expenses of roughly $2.06 million, and a 27% year-to-date expense reduction. Clinically, the near-term roadmap centers on completing Cohort 2 in Australia, securing a DSMB decision by late March on advancing to thrice-weekly dosing in Cohort 3, and continuing SLAMB preclinical work, with the next major update expected alongside the June 2026 annual filing.

The call left investors weighing solid scientific traction against clear financial and operational constraints, with Hemopurifier safety data and expanding EV biology providing the main sources of optimism. With limited cash, higher quarterly losses, and key trial decisions still ahead, Aethlon’s story remains balanced between promising medical innovation and the execution and funding risks that will determine its path forward.